Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 12/20 | 0.57 |
| ▸ | NOS3 | P29474 | 9/20 | 0.57 |
| ▸ | NOS2 | P35228 | 7/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 5/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958723 | 0.96 | NOS1 (0.53) | NOS1NOS3NOS2CHRNB2CHRNA4 | |
| SCHEMBL956120 | 0.96 | NOS1 (0.53) | NOS1NOS3NOS2CHRNB2CHRNA4 | |
| SCHEMBL6584706 | 0.94 | NOS1 (0.64) | NOS1NOS3NOS2CHRNB2CHRNA4 | |
| SCHEMBL6585159 | 0.90 | NOS1 (0.59) | NOS1NOS3NOS2CHRNB2CHRNA4 | |
| SCHEMBL6584246 | 0.90 | NOS1 (0.59) | NOS1NOS3NOS2CHRNB2CHRNA4 | |
| SCHEMBL6585604 | 0.84 | NOS1 (0.61) | NOS1NOS3NOS2CHRNB2CHRNA4 | |
| SCHEMBL6583994 | 0.82 | NOS3 (0.41) | NOS1NOS3NOS2CHRNB2CHRNA4 | |
| SCHEMBL218712 | 0.81 | NOS1 (0.65) | NOS1NOS3NOS2CHRNB2CHRNA4 | |
| SCHEMBL6583707 | 0.77 | FEN1 (0.43) | NOS1NOS3NOS2 | |
| SCHEMBL6582620 | 0.77 | FEN1 (0.42) | NOS1NOS3NOS2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-11-26 | — | — | US | disclosed |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
| EP-1910385-B1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS INC (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20110009496-A1 | RESVERATROL FORMULATIONS | SIRTRIS PHARMACEUTICAS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20070248590-A1 | Modulators of CDC2-like kinases (CLKS) and methods of use thereof | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009496-A1 | RESVERATROL FORMULATIONS | SIRT1, SIRT5, SIRT2 | NOS1 728/4885NOS3 1835/4885NOS2 1029/4885 |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | NNT, CS, ME2 | NOS1 1659/4885NOS3 1327/4885NOS2 1778/4885 |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | NNT, CS, ME2 | NOS1 1659/4885NOS3 1327/4885NOS2 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.